At the Panacea Biotec office, conversations around DengiAll are cloaked with an air of eagerness. With the human trials enrollment ending with over 10,000 participants, the company is waiting for approval.
With govt's local clinical trials waiver for certain drugs and vaccines, Japanese firm Takeda may soon launch QDenga, which will be a boost for India’s fight against dengue.
Study raises need for vaccines to protect those who have not been infected. 619 children in 3 hospitals across India were part of study, published in Nature Medicine in February.
Takeda's QDENGA, designed to protect against all 4 dengue virus serotypes, has been recommended by Strategic Advisory Group of Experts on Immunization for use in endemic countries.
While the rest of the world has converged on a model—technical judgement inside the institution, as a permanent organisational property—India remains a conspicuous and costly outlier.
The shipment earlier bound for Gujarat’s Vadinar has changed course amid payment concerns; could still reach India if issues are resolved, according to Kpler.
INS Arihant was first vessel under SSBN project and was quietly commissioned in 2016. The second indigenous SSBN, INS Arighat, was commissioned in August 2024.
It’s easy to understand why the government can’t speak the hard truth. When this war ends, as all wars do, India’s interests will lie with both the winner and the loser.
COMMENTS